We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · January 13, 2021

Outcomes of Neoadjuvant Chemotherapy as Treatment for Resectable Malignant Pleural Mesothelioma

Journal of the National Cancer Institute


Additional Info

Journal of the National Cancer Institute
The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma–An Institutional and National Analysis
J. Natl. Cancer Inst 2020 Nov 01;112(11)1118-1127, SL Voigt, V Raman, OK Jawitz, M Bishawi, CJ Yang, BC Tong, TA D'Amico, DH Harpole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading